论文部分内容阅读
目的观察蚓激酶联合奥扎格雷钠治疗急性脑梗塞的疗效。方法选择急性脑梗塞患者90例,将其随机分为两组,治疗组45例,对照组45例。两组除常规用药外,治疗组采用蚓激酶(60wu)po,tid;奥扎格雷钠80mg加入5%葡萄糖或生理盐水250ml静脉滴注,每天2次,共14天。对照组中奥扎格雷钠治疗方案同治疗组。两组患者定期行神经功能缺损评分(NDS)并进行比较。结果治疗组与对照组总有效率分别为84.5%和61.2%,组间比较,治疗组治疗后总有效率较对照组高(P<0.05)。NDS下降,与对照组比较,差异有显著性差异(P均<0.01);血液流变学指标明显改善,治疗前后比较,差异有高度显著性(P均<0.01)。两组均无不良反应。结论蚓激酶联合奥扎格雷钠治疗急性脑梗塞安全有效,能有效降低纤维蛋白原及血浆黏度,具有抗血小板聚集作用,同时具有扩张血管、增加脑血流量的作用,可明显改善临床症状,改善神经功能缺损。
Objective To observe the efficacy of lumbrokinase combined with ozagrel sodium in the treatment of acute cerebral infarction. Methods 90 patients with acute cerebral infarction were selected and randomly divided into two groups: 45 cases in the treatment group and 45 cases in the control group. In addition to routine use of the two groups, the treatment group using lumbrokinase (60wu) po, tid; Ozagrel sodium 80mg added 5% glucose or saline 250ml intravenous infusion, 2 times a day for a total of 14 days. Ozagrel sodium treatment in the control group with the treatment group. Two groups of patients underwent regular neurological deficit score (NDS) and compared. Results The total effective rates of the treatment group and the control group were 84.5% and 61.2%, respectively. After treatment, the total effective rate of the treatment group was higher than that of the control group (P <0.05). NDS decreased compared with the control group, the difference was significant (P all <0.01); Hemorheological parameters significantly improved before and after treatment, the difference was highly significant (P all <0.01). No adverse reactions in both groups. Conclusion Lumbrokinase combined with ozagrel sodium in the treatment of acute cerebral infarction is safe and effective, which can effectively reduce the fibrinogen and plasma viscosity, and has the anti-platelet aggregation effect. Meanwhile, it has the function of dilating blood vessels and increasing cerebral blood flow, which can obviously improve clinical symptoms and improve Neurological deficit.